Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP

Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Guest: Megan Kruse, MD

When treating patients with metastatic breast cancer, effective communication and patient support are key. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains how to align treatment goals with patient values, address physical and emotional needs through multidisciplinary support, and incorporate integrative medicine approaches.

Host: Megan Kruse, MD

When treating patients with HER2-positive metastatic breast cancer, understanding how to monitor and manage potential side effects is essential for optimal care. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains key considerations for managing side effects from tucatinib and trastuzumab deruxtecan.

Guest: Fernando López-Ríos, MD, PhD

Guest: Christian Rolfo, MD, PhD

Guest: Charlie Gourley, MD, PhD

In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.

Topics of conversation include the following:

• An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
• Targeting HER2 in lung cancer: where does IHC testing fit in?
• Ovarian cancer: challenges and considerations for HER2 IHC testing

Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.

The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Guest: Sara Horst, MD, MPH, FACG

While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Karin J. Blakemore, MD

Guest: Emilie L. Vander Haar

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD

Guest: Emilie L. Vander Haar

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD

Guest: Emilie L. Vander Haar

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD

Guest: Emilie L. Vander Haar

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD

Guest: Emilie L. Vander Haar

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.